Acute intracranial hemorrhage sensitivity
92 percent
- EndpointCase-level triage sensitivity
- Population360 adult noncontrast head CT cases from more than 30 U.S. sites
- Tested versionAccipiolx configuration described in K182177
FDA-cleared profile
MaxQ-Al Ltd. · CT/CTA · FDA-cleared (510(k))
Authorized purpose: Accipiolx prioritizes adult noncontrast head CT studies for cases with acute intracranial hemorrhage by sending studies from PACS to an analysis engine and returning case-level worklist priority; it is not a standalone diagnostic or rule-out system.
Overview status: Source-reviewed overview
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
Clinical takeaway. Clinical role: Accipiolx prioritizes adult noncontrast head CT studies for cases with acute intracranial hemorrhage by sending studies from PACS to an analysis engine and returning case-level worklist priority; it is not a standalone diagnostic or rule-out system.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports a retrospective study of device sensitivity and specificity on 360 non-contrast head CT cases collected from over 30 US sites, with ground truth established by concurrence of at least two expert neuroradiologist readers. Sensitivity was 92% (95% CI: 87.29-95.68%) and specificity 86% (95% CI: 80.18-90.81%), exceeding the predefined performance goals; average per-case processing time was 4.1 minutes (95% CI: 3.8-4.3 minutes). Results are as reported in the FDA submission, not independent validation.
Evidence context not reviewed for this FDA record.
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Packet wording: "MaxQ-AI conducted a retrospective study to test the sensitivity and specificity of AccipioIx in processing non-contrast head CT cases with a high or low probability of intracranial hemorrhage (ICH)." … "Device sensitivity and specificity was compared to ground truth established by concurrence of at least two expert neuroradiologist readers.". Read from the exact FDA decision document on 2026-11-14.
Evidence
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Packet wording: "MaxQ-AI conducted a retrospective study to test the sensitivity and specificity of AccipioIx in processing non-contrast head CT cases with a high or low probability of intracranial hemorrhage (ICH)." … "Device sensitivity and specificity was compared to ground truth established by concurrence of at least two expert neuroradiologist readers.". Read from the exact FDA decision document on 2026-11-14.
Packet wording: "MaxQ-AI conducted a retrospective study to test the sensitivity and specificity of AccipioIx in processing non-contrast head CT cases with a high or low probability of intracranial hemorrhage (ICH)." … "Analysis of 360 cases collected from over 30 US sites demonstrated system sensitivity and specificity of 92% (95% CI: 87.29-95.68%) and 86% (95% CI: 80.18-90.81%), respectively.". Read from the exact FDA decision document on 2026-11-14; this is the submission-reported standalone result, not independent validation.
Packet wording: "MaxQ-AI conducted a retrospective study to test the sensitivity and specificity of AccipioIx in processing non-contrast head CT cases with a high or low probability of intracranial hemorrhage (ICH)." … "Analysis of 360 cases collected from over 30 US sites demonstrated system sensitivity and specificity of 92% (95% CI: 87.29-95.68%) and 86% (95% CI: 80.18-90.81%), respectively.". Read from the exact FDA decision document on 2026-11-14; this is the submission-reported standalone result, not independent validation.
92 percent
86 percent
4.1 minutes
K182177
The FDA package reports sensitivity, specificity, and average processing time for the exact Accipiolx study.
Safety and lifecycle
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Exact-identifier review does not prove absence of all product-family safety signals.
Price not public here; enter your quote
Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.
No separate named-product payment identified in reviewed public material
Centers for Medicare & Medicaid Services · United StatesThis is not a product-specific reimbursement determination. Build a local total-cost and value model and verify payer, site-of-service, coding, and coverage assumptions independently.
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Source context, not route validation: Adult noncontrast head CT studies transferred from PACS.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Field checked 2026-09-04 · FDA 510(k) decision material K182177: Accipiolx
Source context, not route validation: The FDA package describes transfer of adult noncontrast head CT from PACS to an analysis engine and return of case-level priority to the worklist.
Scope: Exact FDA submission. This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Field checked 2026-09-04 · FDA 510(k) decision material K182177: Accipiolx
Source context, not route validation: The FDA package describes installation in a healthcare radiology network; current hosting, service, security, availability, and upgrade boundaries remain unverified.
Scope: Exact FDA submission. This is the release-level boundary described in the exact FDA package; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-04 · FDA 510(k) decision material K182177: Accipiolx
Source context, not route validation: Case-level worklist priority returned to the radiology workflow.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Field checked 2026-09-04 · FDA 510(k) decision material K182177: Accipiolx
Unresolved route: Case-level worklist priority returned to the radiology workflow.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Field checked 2026-09-04 · FDA 510(k) decision material K182177: Accipiolx
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
No tests below have been performed or accepted.
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
This is the release-level boundary described in the exact FDA package; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence.
This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.
Monitoring guidance is buyer-facing implementation guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.
Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K182177 before acceptance.
exact submission · checked 2026-09-04Later product-family features are not evidence that this cleared release includes them.
The FDA package describes installation in a healthcare radiology network; current hosting, service, security, availability, and upgrade boundaries remain unverified.
exact submission · checked 2026-09-04FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.
The FDA package describes transfer of adult noncontrast head CT from PACS to an analysis engine and return of case-level priority to the worklist.
exact submission · checked 2026-09-04Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Accipiolx prioritizes eligible adult noncontrast head CT cases but is not a standalone diagnosis, rule-out, or replacement for complete physician review.
exact submission · checked 2026-09-04Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-04No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.
Monitor K182177 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Accipiolx prioritizes eligible adult noncontrast head CT cases but is not a standalone diagnosis, rule-out, or replacement for complete physician review.
exact submission · checked 2026-09-04Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. acute intracranial-hemorrhage triage software limits remain submission-specific.
Regulatory identity
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
Research record
This audit distinguishes completed source review from fields that have not yet been researched.
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.
7 sources - 3 history items
Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary
Scope: regulatoryIdentity, modalityContext
Scope: evidenceDiscovery
Scope: evidenceDiscovery, studyStatus
Scope: coverage, codingContext
Scope: recallDiscovery, nativeSubmissionMatching
Regulatory record
510(k)
Research record
human reviewed
Editorial review
Source-reviewed editorial overlay
Alternatives
JLK, Inc.
Authorized purpose: Notification-only triage of adult non-contrast head CT for suspected intracranial hemorrhage and large-vessel occlusion, with parallel communication to trained clinicians during standard care.
Mlhealth 360
Authorized purpose: Non-contrast head CT triage for suspected intracranial hemorrhage in adults aged 22 and older.
Brainomix Limited
Authorized purpose: Triage and notification of suspected intracranial hemorrhage or anterior-circulation LVO on acute non-contrast head CT; not primary diagnosis.
Methinks Software S.L.
Authorized purpose: Methinks CTA Stroke analyzes acute-setting brain CT angiography in adults over 21 with suspected stroke for suspected large-vessel occlusion in the terminal ICA, MCA-M1, or MCA-M2 and sends PACS and/or specialist notifications in parallel to standard care; previews are informational and not diagnostic.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Open existing correction destinationPermission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.
Correction policy and limits · Public repository change history